Concetta Ragone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Concetta Ragone has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Angela Mauriello
Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS – “Fond G. Pascale”, Naples, Italy
5 shared publications - Beatrice Cavalluzzo
Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Naples, Italy
5 shared publications - Luigi Buonaguro
Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - “Fond G. Pascale”, Naples, Italy
5 shared publications - Maria Tagliamonte
Innovative Immunological Models Unit, National Cancer Institute IRCCS - “Fond G. Pascale”, Italy
5 shared publications - Carmen Manolio
Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS – “Fond G. Pascale”, Naples, Italy
4 shared publications - Franco Maria Buonaguro
Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy
3 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Scilight Press Pty Ltd in Translational Insights
- Vol. 1 (1) , 14
Molecular Mimicry in the Dark Immunopeptidome: Viral-Homologous Non-Canonical Tumor Peptides as Targets for Off-the-Shelf Cancer Vaccines
Background: The identification of broadly shared, highly immunogenic tumor antigens remains a central challenge in cancer vaccine development. Non-canonical tumor peptides (nonC-TPs) arising from the cancer “dark genome” have recently emerged as a highly immunogenic class of tumor antigens with strong potential for off-the-shelf cancer vaccine development. These peptides originate from aberrant transcriptional and translational events involving transposable elements, endogenous retroviruses, untranslated regions, and alternative open reading frames, represent a promising antigen class, as they are absent from normal tissues, largely excluded from thymic selection, and shared across tumor histologies and patients. Molecular mimicry between tumor antigens and viral epitopes has been previously demonstrated for canonical tumor-associated antigens (TAAs), providing a mechanistic basis for cross-reactive anti-tumor immunity mediated by virus-specific memory T cells. This has never been investigated in the nonC-TP landscape of the dark genome. Methods: Starting from the proteogenomic dataset generated by Lozano-Rabella, comprising 65,504 canonical and non-canonical peptides identified in several primary cancer cell lines, we prioritized 244 tumor-exclusive non-canonical nonamers predicted as strong HLA binders using NetMHCpan4.1. Then we focused our analysis on restricted NonC peptides binding four HLA-A allotypes. Homology searches against viral proteomes were performed using BLAST, followed by HLA binding and stability prediction with NetMHCstabpan1.0. Structural modelling and molecular docking analyses were conducted to evaluate conservation of peptide-HLA molecular conformations between nonC peptides and viral homologs. Results: A significant subset of dark genome-derived nonC TPs displayed significant sequence homology with viral epitopes across multiple HLA-A alleles, particularly HLA-A*02:01, HLA-A*03:01, and HLA-A*11:01. Homologous viral sequences were identified from clinically relevant pathogens. The homologous peptides frequently conserved amino acid residues predicted to mediate TCR interaction, supporting the possibility of cross-reactive recognition by pre-existing anti-viral memory CD8+ T cells. Structural modelling further demonstrated highly similar peptide-HLA docking conformations between nonC peptides and their viral counterparts, supporting the potential role of molecular mimicry within the dark immunopeptidome. Conclusions: This study provides the first systematic evidence that dark genome-derived nonC-TPs exhibit molecular mimicry with viral antigens, extending a well-established immunological paradigm to a previously unexplored antigen class. The identified viral-homologous nonC-TPs combine tumor specificity, broad sharing across patients and histologies, and potential recognition by pre-existing virus-specific memory T cells, positioning them as uniquely attractive candidates for next-generation, off-the-shelf cancer vaccines. These findings open a new dimension of tumor immunosurveillance and provide a rational framework for the development of immunotherapeutic strategies that exploit the convergence of dark genome biology, molecular mimicry, and viral mimicry.
- 21 July 2026
- Published by Scilight Press Pty Ltd in Translational Insights
- Vol. 1 (1) , 14
Open AccessMolecular Mimicry in the Dark Immunopeptidome: Viral-Homologous Non-Canonical Tumor Peptides as Targets for Off-the-Shelf Cancer Vaccines
Background: The identification of broadly shared, highly immunogenic tumor antigens remains a central challenge in cancer vaccine development. Non-canonical tumor peptides (nonC-TPs) arising from the cancer “dark genome” have recently emerged as a highly immunogenic class of tumor antigens with strong potential for off-the-shelf cancer vaccine development. These peptides originate from aberrant transcriptional and translational events involving transposable elements, endogenous retroviruses, untranslated regions, and alternative open reading frames, represent a promising antigen class, as they are absent from normal tissues, largely excluded from thymic selection, and shared across tumor histologies and patients. Molecular mimicry between tumor antigens and viral epitopes has been previously demonstrated for canonical tumor-associated antigens (TAAs), providing a mechanistic basis for cross-reactive anti-tumor immunity mediated by virus-specific memory T cells. This has never been investigated in the nonC-TP landscape of the dark genome. Methods: Starting from the proteogenomic dataset generated by Lozano-Rabella, comprising 65,504 canonical and non-canonical peptides identified in several primary cancer cell lines, we prioritized 244 tumor-exclusive non-canonical nonamers predicted as strong HLA binders using NetMHCpan4.1. Then we focused our analysis on restricted NonC peptides binding four HLA-A allotypes. Homology searches against viral proteomes were performed using BLAST, followed by HLA binding and stability prediction with NetMHCstabpan1.0. Structural modelling and molecular docking analyses were conducted to evaluate conservation of peptide-HLA molecular conformations between nonC peptides and viral homologs. Results: A significant subset of dark genome-derived nonC TPs displayed significant sequence homology with viral epitopes across multiple HLA-A alleles, particularly HLA-A*02:01, HLA-A*03:01, and HLA-A*11:01. Homologous viral sequences were identified from clinically relevant pathogens. The homologous peptides frequently conserved amino acid residues predicted to mediate TCR interaction, supporting the possibility of cross-reactive recognition by pre-existing anti-viral memory CD8+ T cells. Structural modelling further demonstrated highly similar peptide-HLA docking conformations between nonC peptides and their viral counterparts, supporting the potential role of molecular mimicry within the dark immunopeptidome. Conclusions: This study provides the first systematic evidence that dark genome-derived nonC-TPs exhibit molecular mimicry with viral antigens, extending a well-established immunological paradigm to a previously unexplored antigen class. The identified viral-homologous nonC-TPs combine tumor specificity, broad sharing across patients and histologies, and potential recognition by pre-existing virus-specific memory T cells, positioning them as uniquely attractive candidates for next-generation, off-the-shelf cancer vaccines. These findings open a new dimension of tumor immunosurveillance and provide a rational framework for the development of immunotherapeutic strategies that exploit the convergence of dark genome biology, molecular mimicry, and viral mimicry.
- Open Access
- 15 October 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-20
Antigenic molecular mimicry in viral-mediated protection from cancer: the HIV case
Background: People living with HIV/AIDS (PLWHA) show a reduced incidence for three cancer types, namely breast, prostate and colon cancers. In the present study, we assessed whether a molecular mimicry between HIV epitopes and tumor associated antigens and, consequently, a T cell cross-reactivity could provide an explanation for such an epidemiological evidence. Methods: Homology between published TAAs and non-self HIV-derived epitopes have been assessed by BLAST homology. Structural analyses have been performed by bioinformatics tools. Immunological validation of CD8+ T cell cross-reactivity has been evaluated ex vivo by tetramer staining. Findings: Sequence homologies between multiple TAAs and HIV epitopes have been found. High structural similarities between the paired TAAs and HIV epitopes as well as comparable patterns of contact with HLA and TCR α and β chains have been observed. Furthermore, cross-reacting CD8+ T cells have been identified. Interpretation: This is the first study showing a molecular mimicry between HIV antigens an TAAs identified in breast, prostate and colon cancers. Therefore, it is highly reasonable that memory CD8+ T cells elicited during the HIV infection may play a key role in controlling development and progression of such cancers in the PLWHA lifetime. This represents the first demonstration ever that a viral infection may induce a natural “preventive” anti-cancer memory T cells, with highly relevant implications beyond the HIV infection.
- 15 October 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-20
Open AccessAntigenic molecular mimicry in viral-mediated protection from cancer: the HIV case
Background: People living with HIV/AIDS (PLWHA) show a reduced incidence for three cancer types, namely breast, prostate and colon cancers. In the present study, we assessed whether a molecular mimicry between HIV epitopes and tumor associated antigens and, consequently, a T cell cross-reactivity could provide an explanation for such an epidemiological evidence. Methods: Homology between published TAAs and non-self HIV-derived epitopes have been assessed by BLAST homology. Structural analyses have been performed by bioinformatics tools. Immunological validation of CD8+ T cell cross-reactivity has been evaluated ex vivo by tetramer staining. Findings: Sequence homologies between multiple TAAs and HIV epitopes have been found. High structural similarities between the paired TAAs and HIV epitopes as well as comparable patterns of contact with HLA and TCR α and β chains have been observed. Furthermore, cross-reacting CD8+ T cells have been identified. Interpretation: This is the first study showing a molecular mimicry between HIV antigens an TAAs identified in breast, prostate and colon cancers. Therefore, it is highly reasonable that memory CD8+ T cells elicited during the HIV infection may play a key role in controlling development and progression of such cancers in the PLWHA lifetime. This represents the first demonstration ever that a viral infection may induce a natural “preventive” anti-cancer memory T cells, with highly relevant implications beyond the HIV infection.
- Open Access
- 14 July 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-18
Molecular mimicry between tumor associated antigens and microbiota-derived epitopes
Background: The gut microbiota profile is unique for each individual and are composed by different bacteria species according to individual birth-to-infant transitions. In the last years, the local and systemic effects of microbiota on cancer onset, progression and response to treatments, such as immunotherapies, has been extensively described. Here we offer a new perspective, proposing a role for the microbiota based on the molecular mimicry of tumor associated antigens by microbiome-associated antigens. Methods: In the present study we looked for homology between published TAAs and non-self microbiota-derived epitopes. Blast search for sequence homology was combined with extensive bioinformatics analyses. Results: Several evidences for homology between TAAs and microbiota-derived antigens have been found. Strikingly, three cases of 100% homology between the paired sequences has been identified. The predicted average affinity to HLA molecules of microbiota-derived antigens is very high (< 100 nM). The structural conformation of the microbiota-derived epitopes is, in general, highly similar to the corresponding TAA. In some cases, it is identical and contact areas with both HLA and TCR chains are indistinguishable. Moreover, the spatial conformation of TCR-facing residues can be identical in paired TAA and microbiota-derived epitopes, with exactly the same values of planar as well as dihedral angles. Conclusions: The data reported in the present study show for the first time the high homology in the linear sequence as well as in structure and conformation between TAAs and peptides derived from microbiota species of the Firmicutes and the Bacteroidetes phyla, which together account for 90% of gut microbiota. Cross-reacting CD8+ T cell responses are very likely induced. Therefore, the anti-microbiota T cell memory may turn out to be an anti-cancer T cell memory, able to control the growth of a cancer developed during the lifetime if the expressed TAA is similar to the microbiota epitope. This may ultimately represent a relevant selective advantage for cancer patients and may lead to a novel preventive anti-cancer vaccine strategy.
- 14 July 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-18
Open AccessMolecular mimicry between tumor associated antigens and microbiota-derived epitopes
Background: The gut microbiota profile is unique for each individual and are composed by different bacteria species according to individual birth-to-infant transitions. In the last years, the local and systemic effects of microbiota on cancer onset, progression and response to treatments, such as immunotherapies, has been extensively described. Here we offer a new perspective, proposing a role for the microbiota based on the molecular mimicry of tumor associated antigens by microbiome-associated antigens. Methods: In the present study we looked for homology between published TAAs and non-self microbiota-derived epitopes. Blast search for sequence homology was combined with extensive bioinformatics analyses. Results: Several evidences for homology between TAAs and microbiota-derived antigens have been found. Strikingly, three cases of 100% homology between the paired sequences has been identified. The predicted average affinity to HLA molecules of microbiota-derived antigens is very high (< 100 nM). The structural conformation of the microbiota-derived epitopes is, in general, highly similar to the corresponding TAA. In some cases, it is identical and contact areas with both HLA and TCR chains are indistinguishable. Moreover, the spatial conformation of TCR-facing residues can be identical in paired TAA and microbiota-derived epitopes, with exactly the same values of planar as well as dihedral angles. Conclusions: The data reported in the present study show for the first time the high homology in the linear sequence as well as in structure and conformation between TAAs and peptides derived from microbiota species of the Firmicutes and the Bacteroidetes phyla, which together account for 90% of gut microbiota. Cross-reacting CD8+ T cell responses are very likely induced. Therefore, the anti-microbiota T cell memory may turn out to be an anti-cancer T cell memory, able to control the growth of a cancer developed during the lifetime if the expressed TAA is similar to the microbiota epitope. This may ultimately represent a relevant selective advantage for cancer patients and may lead to a novel preventive anti-cancer vaccine strategy.
- Open Access
Novel Molecular Targets for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, only a few treatments are available, most of which are effective only for the early stages of the disease. Therefore, there is an urgent needing for potential markers for a specifically targeted therapy. Candidate proteins were selected from datasets of The Human Protein Atlas, in order to identify specific tumor-associated proteins overexpressed in HCC samples associated with poor prognosis. Potential epitopes were predicted from such proteins, and homology with peptides derived from viral proteins was assessed. A multiparametric validation was performed, including recognition by PBMCs from HCC-patients and healthy donors, showing a T-cell cross-reactivity with paired epitopes. These results provide novel HCC-specific tumor-associated antigens (TAAs) for immunotherapeutic anti-HCC strategies potentially able to expand pre-existing virus-specific CD8+ T cells with superior anticancer efficacy.
Open AccessNovel Molecular Targets for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, only a few treatments are available, most of which are effective only for the early stages of the disease. Therefore, there is an urgent needing for potential markers for a specifically targeted therapy. Candidate proteins were selected from datasets of The Human Protein Atlas, in order to identify specific tumor-associated proteins overexpressed in HCC samples associated with poor prognosis. Potential epitopes were predicted from such proteins, and homology with peptides derived from viral proteins was assessed. A multiparametric validation was performed, including recognition by PBMCs from HCC-patients and healthy donors, showing a T-cell cross-reactivity with paired epitopes. These results provide novel HCC-specific tumor-associated antigens (TAAs) for immunotherapeutic anti-HCC strategies potentially able to expand pre-existing virus-specific CD8+ T cells with superior anticancer efficacy.
- Open Access
Human Endogenous Retrovirus Reactivation: Implications for Cancer Immunotherapy
Human endogenous retroviruses (HERVs) derive from ancestral exogenous retroviruses whose genetic material has been integrated in our germline DNA. Several lines of evidence indicate that cancer immunotherapy may benefit from HERV reactivation, which can be induced either by drugs or by cellular changes occurring in tumor cells. Indeed, several studies indicate that HERV proviral DNA can be transcribed either to double-stranded RNA (dsRNA) that is sensed as a “danger signal” by pattern recognition receptors (PRRs), leading to a viral mimicry state, or to mRNA that is translated into proteins that may contribute to the landscape of tumor-specific antigens (TSAs). Alternatively, HERV reactivation is associated with the expression of long noncoding RNAs (lncRNAs). In this review, we will highlight recent findings on HERV reactivation in cancer and its implications for cancer immunotherapy.
Open AccessHuman Endogenous Retrovirus Reactivation: Implications for Cancer Immunotherapy
Human endogenous retroviruses (HERVs) derive from ancestral exogenous retroviruses whose genetic material has been integrated in our germline DNA. Several lines of evidence indicate that cancer immunotherapy may benefit from HERV reactivation, which can be induced either by drugs or by cellular changes occurring in tumor cells. Indeed, several studies indicate that HERV proviral DNA can be transcribed either to double-stranded RNA (dsRNA) that is sensed as a “danger signal” by pattern recognition receptors (PRRs), leading to a viral mimicry state, or to mRNA that is translated into proteins that may contribute to the landscape of tumor-specific antigens (TSAs). Alternatively, HERV reactivation is associated with the expression of long noncoding RNAs (lncRNAs). In this review, we will highlight recent findings on HERV reactivation in cancer and its implications for cancer immunotherapy.